Trial Profile
Enhanced efficacy of photodynamic therapy in combination with 5% imiquimod -a randomised, prospective, observer-blinded study in patients with non melanoma skin cancer [Erhöhte Wirksamkeit der photodynamischen Therapie durch Kombination mit 5% Imiquimod?- eine randomisierte, prospektive Studie in Patienten mit nicht melanozytären Hauttumoren]
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary) ; Aminolevulinic acid
- Indications Basal cell cancer; Skin cancer
- Focus Therapeutic Use
- Acronyms PDT vs. PDT and 5% Imiquimod in patients with NMSC
- 27 Oct 2022 Status changed from recruiting to discontinued.
- 11 Nov 2013 New trial record